Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: A property of protein kinase C-mediated mood stabilizers

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 307-316

  Watson, David G ^a   Watterson, Jeannette M ^a   Lenox, Robert H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBACHOL; CARBAMAZEPINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; INOSITOL; LITHIUM; MARCKS PROTEIN; MORPHINE SULFATE; PROTEIN KINASE C; PSYCHOTROPIC AGENT; VALPROIC ACID;

ANIMAL CELL; ARTICLE; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; MANIC DEPRESSIVE PSYCHOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOPHARMACOTHERAPY;

ANIMALS; ANTIMANIC AGENTS; CARBACHOL; CELLS, CULTURED; CHO CELLS; CRICETINAE; CYTIDINE MONOPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; GLYCEROPHOSPHOLIPIDS; HIPPOCAMPUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LITHIUM CHLORIDE; MEMBRANE PROTEINS; MUSCARINIC AGONISTS; PHOSPHATIDIC ACIDS; PROTEIN KINASE C; PROTEINS; VALPROIC ACID;

EID: 0031981038     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Aderem A (1992) The MARCKS brothers: A family of protein kinase C substrates. Cell 71:713-716.
2. + in the treatment of bipolar disorder. Trends Neurosci 18:343-349.
3. Atack JR, Prior AM, Griffith D and Ragan CI (1993) Characterization of the effects of lithium in phosphatidylinositol (PI) cycle activity in human muscarinic m1 receptor-transfected CHO cells. Br J Pharmacol 110:809-815.
4. Benet LZ and Williams RL (1990) Pharmacokinetic data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, ed. by A. G. Gilman, T. W. Rall, A. S. Nies and P. Taylor, pp. 1655-1715, Pergamon Press, Elmsford, NY.
5. Berridge MJ (1989) Inositol triphosphate, calcium, lithium, and cell signaling. JAMA 262:1834-1841.
6. Berridge MJ, Downes CP and Hanley MR (1989) Neural and developmental actions of lithium: A unifying hypothesis. Cell 59:411-419.
7. Berridge MJ, Downes CP and Hanley MR (1982) Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 206:587-595.
8. Blackshear PJ (1993) The MARCKS family of cellular protein kinase C substrates. J Biol Chem 268:1501-1504.
9. Bowden CL (1996) Lithium comparison to valproate and carbamazepine. Eur. Neuropsychopharmacology 6(Suppl. 3):85.
10. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ and Morris DD (1994) Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 271:918-924.
11. Brooks SF, Herget T, Broad S and Rozengurt E (1992) The expression of 80K/ MARCKS, a major substrate of protein kinase C (PKC), is down-regulated through PKC-dependent and -independent pathways. J Biol Chem 267:14212-14218.
12. Brooks SF, Herget T, Erusalimsky JD and Rozengurt E (1991) Protein kinase C activation potently down-regulates the expression of its major substrate, 8oK, in Swiss 3T3 cells. EMBO J 10:2497-2505.
13. Calabrese JR and Delucchi GA (1989) Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 50 (3suppl.):30-34.
14. Calabrese JR and Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431-434.
15. Calabrese JR, Markovitz PJ, Kimmel SE and Wagner SC (1992) Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 12:53S-56S.
16. Calabrese JR, Rapport DJ, Kimmel SE, Reece B and Woyshville MJ (1993) Rapidcycling bipolar disorder and its treatment with valproate. Can J Psychiatry 38 (suppl. 2):S57-S61.
17. Chapman A, Keane PE, Meldrum BS, Simiand J and Verniers JC (1982) Mechanism of anticonvulsant action of valproate. Prog Neurobiol 19:315-359.
18. Chen G, Manji HK, Hawver DB, Wright CB and Potter WZ (1994) Chronic sodium valproate selectively decreases protein kinase C α and ∈ in vitro. J Neurochem 63:2361-2364.
19. Chen G, Manji HK, Wright CB, Hawver DB and Potter WZ (1996) Effects of valproic acid on β-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 15:271-280.
20. Downes CP and Stone MA (1986) Lithium-induced reduction in intracellular inositol supply in cholinergically stimulated parotid gland. Biochem J 234:199-204.
21. Drummond AH and Raeburn CA (1984) The interaction of lithium with thyrotropin releasing hormone-stimulated lipid metabolism in GH3 pituitary tumor cells. Biochem J 224:129-136.
22. Faedda GL, Tondo L, Baldessarini RJ, Suppes T and Tohen M (1993) Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 50:448-455.
23. Gerner RH and Stanton A (1992) Algorithm for patient management of acute manicstates: Lithium, valproate, or carbamazepine? J Clin Psychopharmacol 12:57S-63S.
24. Godfrey PP (1989) Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol. Biochem J 258:621-624.
25. Goldberg JF, Harrow M and Grossman LS (1995) Recurrent affective syndromes in bipolar and unipolar mood disorders at follow-up. Br J Psychiatry 166:382-385.
26. Goodwin FK and Jamison KR (1990) Manic-Depressive Illness. Oxford University Press, New York.
27. Hayes SG (1989) Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 50 (3 suppl.):35-39.
28. Holford NHG and Benet LZ (1995) Pharmacokinetics and pharmacodynamics: Rational dose selection and the time course of drug action. In Basic and Clinical Pharmacology, 6th ed., ed. by B. G. Katzung, pp. 35-36, Appleton & Lange, Norwalk, CT.
29. Jenkinson S, Nahorski SR and Challiss RAJ (1994) Disruption by lithium of phosphatidylinositol-4,5-bisphosphate supply and inositol-1,4,5-trisphosphate generation in Chinese hamster ovary cells expressing human recombinant m1 muscarinic receptors. Mol Pharmacol 46:1138-1148.
30. Keck PE, McElroy SL and Nemeroff CB (1992) Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry 4:395-405.
31. Kennedy ED, Challiss RAJ, Ragan CI and Nahorski SR (1990) Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochem J 267:781-786.
32. Lee HJ, Hammond DN, Large TH, Roback JD, Sim JA, Brown DA, Otten UH and Wainer BH (1990) Neuronal properties and trophic activities of immortalized hippocampal cells from embryonic and young adult mice. J Neurosci 10:1779-1787.
33. Lenox RH (1988) Lithium interaction with the phosphoinositide system and protein kinase C in the nervous system. In Progress in Catecholamine Research, Vol. 42C, ed. by R. H. Belmaker, M. Sandler and A. Dahlatrom, pp. 327-335, Alan Liss, New-York.
34. Lenox RH (1987) Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. In Molecular Mechanisms of Neuronal Responsiveness, Adv. Exp. Biol. Med. Vol. 221, ed. by Y. H. Ehrlich, R. H. Lenox, E. Kornecki and W. O. Berry, pp. 515-530, Plenum Press, New York.
35. Lenox RH and Manji HK (1995) Lithium. In APA Textbook of Psychopharmacology, ed. by C. Nemeroff and A. Schatzberg, pp. 303-349, APA Press, Washington, DC.
36. Lenox RH and Watson DG (1994) Lithium and the brain: A psychopharmacological strategy to a molecular basis for manic-depressive illness. Clin Chem 40:309-314.
37. Lenox RH, Watson DG, Patel J and Ellis J (1992) Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 570:333-340.
38. Lindner D, Gschwendt M and Marks F (1992) Phorbol ester-induced down-regulation of the 80-kDa myristoylated alanine-rich C kinase substrate-related protein in Swiss 3T3 fibroblasts. J Biol Chem 267:24-26.
39. Loscher W (1993) Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 18:485-502.
40. Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI and Potter WZ (1996) Regulation of signal transduction pathways by mood-stabilizing agents: Implications for the delayed onset of therapeutic efficacy. J Clin Psych 57 (suppl. 13):34-46.
41. Manji HK, Etcheberrigaray R, Chen G and Olds JL (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: Selectivity for the α isozyme. J Neurochem 61:2303-2310.
42. Manji HK and Lenox RH (1994) Long-term action of lithium: A role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 16:11-28.
43. Manji HK, Potter WZ and Lenox RH (1995) Signal transduction pathways: Molecular targets for lithium's action. Arch Gen Psychiatry 52:531-543.
44. Martin ML and Regan CM (1991) The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res 554:223-228.
45. McElroy SL, Keck PE, Pope HG and Hudson JI (1992) Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines. J Clin Psychopharmacol 12:42S-52S.
46. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA and Strakowski SM (1996) A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania, J Clin Psychiatry 57:142-146.
47. Meunier H, Carraz G, Meunier Y, Eymard P and Aimard M (1963) Proprietes pharmacodynamic de l'acide n-depropylacetique: Ler memoire: Proprietes antiepileptiques. Therapie 18:435-438.
48. Mork A, Geisler A and Hollund P (1992) Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 71 (suppl. 1):4-17.
49. Motohashi N (1990) GABA receptor alterations after chronic lithium: In comparison with carbamazepine and sodium valproate. Clin Neuropharmacol 13:207-208.
50. Newton AC (1995) Protein kinase C: Structure, function and regulation. J Biol Chem 270:28495-28498.
51. Nishizuka Y (1995) Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 9:484-496.
52. Petty F (1995) GABA and mood disorders: A brief review and hypothesis. J Affect Disord 34:275-281.
53. Pollack SJ, Atack JR, Knowles MR, McAllister G, Ragan CI, Baker R, Fletcher SR, Iversen LL and Broughton HB (1994) Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci USA 91:5766-5770.
54. Post RM, Leverich GS, Altshuler L and Mikalauskas K (1992a) Lithium discontinuation-induced refractoriness: Preliminary observations. Am J Psychiatry 149: 1727-1729.
55. Post RM, Weiss SRB and Chuang D-M (1992b) Mechanisms of action of anticonvulsants in affective disorders: Comparisons with lithium. J Clin Psychopharmacol 12:23S-35S.
56. Ramsay RE (1984) Controlled and comparative trials with valproate: United States. Epilepsia 25 (suppl. 1):S40-S43.
57. Rana RS and Hokin LE (1990) Role of phosphoinositides in transmembrane signaling. Physiol Rev 70:115-164.
58. Stubbs EB and Agranoff BW (1993) Lithium enhances muscarinic receptor-stimulated CDP-diacylglycerol formation in inositol-depleted SK-N-SH neuroblastoma cells. J Neurochem 60:1292-1299.
59. Suppes T, Baldessarini RJ, Faedda GL and Tohen M (1991) Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 48:1082-1088.
60. Vadnal RE and Parthasarathy R (1995) Myo-inositol monophosphatase: Diverse effects of lithium, carbamazepine, and valproate. Neuropyachyopharmacology 12: 277-285.
61. Waldmeier PC (1987) Is there a common denominator for the antimanic effect of lithium and antidepressants? Pharmacopsychiatry 20:37-47.
62. Watson DG and Lenox RH (1996) Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: Potentiation by muscarinic receptor activation. J Neurochem 67:767-777.
63. Watson DG and Lenox RH (1997) Chronic lithium exposure leads to the down-regulation of both MARCKS mRNA and protein in immortalized hippocampal cells. Soc Neurosci Abstr 23:1111.
64. Watson DG, Wainer BH and Lenox RH (1994) Phorbol ester-and rethnoic acid-induced regulation of the PKC substrate MARCKS in immortalized hippocampal cells. J Neurochem 63:1666-1674.
65. Weiner B (ed) (1996) PDR Generics, 2nd ed, Medical Economics, Montvale, NJ.